← FDA DRUG APPROVALS

FDA ANDA · ANDA215697

PRAZOSIN HYDROCHLORIDE

Sponsor: MANKIND PHARMA

APPLICATION
ANDA215697
TYPE
ANDA
ORIGINAL APPROVAL
2022-12-30
LATEST ACTION
2022-12-30
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

PRAZOSIN HYDROCHLORIDEPrescription
PRAZOSIN HYDROCHLORIDE EQ 2MG BASE · CAPSULE · ORAL
PRAZOSIN HYDROCHLORIDEPrescription
PRAZOSIN HYDROCHLORIDE EQ 5MG BASE · CAPSULE · ORAL
PRAZOSIN HYDROCHLORIDEPrescription
PRAZOSIN HYDROCHLORIDE EQ 1MG BASE · CAPSULE · ORAL

Approval history

2022-12-30UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →